broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K92441787-001-04-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.953611 | -0.137295 | -0.012289 | 0.961376 | 13,218.672256 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000972 |
BRD-K92723993-001-17-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.106251 | -0.016663 | -0.003953 | 1 | 5.734755 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000972 |
BRD-K96123349-236-02-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.7336 | 1.821392 | 0.173435 | 0.952462 | 1.81262 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000972 |
BRD-K98572433-001-02-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.002088 | 0.022651 | -0.000888 | 1 | 0.000239 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000972 |
BRD-K99113996-001-02-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.454157 | 1.969653 | 0.587365 | 0.890574 | 1.445146 | 4.861338 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000972 |
BRD-K99616396-001-05-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.003369 | -0.067535 | -0.018237 | 1 | 8,664.48756 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000972 |
BRD-M97302542-001-04-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.856424 | 3.739686 | 0.238104 | 0.950575 | 0.354105 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000972 |
BRD-A25234499-001-19-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.008693 | -0.083558 | -0.096221 | 1 | 0.366691 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000973 |
BRD-A70858459-001-01-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | -0.315992 | -1.323954 | 0.059631 | 0.975515 | 0.000227 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000973 |
BRD-A74914197-001-02-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.175256 | 1.651549 | 0.868091 | 0.535001 | 0.002626 | 0.00341 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000973 |
BRD-K02113016-001-19-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | -0.012371 | 0.447395 | 0.477163 | 0.724923 | 1.476756 | 1.398245 | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000973 |
BRD-K02130563-001-11-4 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.415553 | -0.228304 | -0.028816 | 0.854793 | 0.000395 | null | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000973 |
BRD-K03390685-001-01-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.088927 | 0.09452 | -0.008799 | 1 | 0.000292 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000973 |
BRD-K03406345-001-21-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.819882 | 0.1083 | -0.005634 | 0.911065 | 0.098864 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000973 |
BRD-K03449891-001-08-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.68839 | 7.30932 | 0.23954 | 0.932756 | 1.23167 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000973 |
BRD-K03765900-001-01-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.200571 | 3.343041 | -0.057301 | 1 | 0.096255 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000973 |
BRD-K05804044-001-18-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.004944 | -0.043238 | -0.009313 | 1 | 873.563871 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000973 |
BRD-K06814349-304-02-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.327444 | 3.984568 | 0.651729 | 0.829602 | 0.855421 | 1.117216 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000973 |
BRD-K08109215-001-06-4 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.073557 | 0.243012 | 0.011511 | 1 | 0.020828 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000973 |
BRD-K08542803-001-02-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.030961 | 0.655308 | 0.512892 | 0.518636 | 0.080832 | 0.089115 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000973 |
BRD-K08547377-001-04-4 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.072565 | 1.240739 | 0.868506 | 0.302514 | 0.00649 | 0.007364 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000973 |
BRD-K08703257-001-13-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.669879 | -1.153619 | 0.034514 | 0.939997 | 0.003153 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000973 |
BRD-K08799216-001-05-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.904694 | 0.062567 | 0.021156 | 1 | 8.439882 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000973 |
BRD-K09951645-001-11-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.309084 | 2.262185 | 0.065642 | 1 | 0.068654 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000973 |
BRD-K11267252-001-05-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.018503 | -0.120322 | -0.007778 | 1 | 0.004782 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000973 |
BRD-K11630072-001-13-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.37322 | 0.521932 | 0.226653 | 0.795717 | 0.596727 | 8.270459 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000973 |
BRD-K12184916-001-19-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.191688 | -0.438545 | 0.091764 | 1 | 0.329161 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000973 |
BRD-K12343256-001-14-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.058771 | -1.037458 | 0.040137 | 1 | 0.036795 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000973 |
BRD-K13049116-001-04-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.684842 | 2.783364 | 0.138863 | 0.920922 | 0.876297 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000973 |
BRD-K13390322-001-06-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.078718 | 0.586669 | 0.817223 | 0.585159 | 0.134407 | 0.179985 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000973 |
BRD-K13514097-001-04-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 2.109395 | 0.103127 | 0.1403 | 1 | 0.036822 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000973 |
BRD-K13662825-001-07-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.037607 | 0.292936 | 0.349365 | 0.39763 | 0.002552 | 0.003333 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000973 |
BRD-K15179879-001-03-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.127996 | 0.700955 | 0.783911 | 0.350122 | 0.005525 | 0.008424 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000973 |
BRD-K15600710-066-05-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.702849 | 6.825743 | 0.179757 | 0.89651 | 0.334344 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000973 |
BRD-K16730910-001-10-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.97877 | -0.139424 | -0.145818 | 0.984978 | 55.288456 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000973 |
BRD-K17555800-003-02-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.13143 | 0.053338 | -0.033727 | 1 | 0.689859 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000973 |
BRD-K17610631-001-03-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.337805 | 0.985776 | 0.575307 | 0.738324 | 0.213543 | 0.669063 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000973 |
BRD-K17743125-001-08-4 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.385287 | 0.210262 | 0.025513 | 1 | 0.631204 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000973 |
BRD-K17894950-001-14-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.957976 | 0.382072 | -0.055355 | 0.969432 | 0.003157 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000973 |
BRD-K18961567-001-01-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.261526 | 1.843672 | 0.493169 | 0.859024 | 1.59691 | 2.386032 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000973 |
BRD-K19540840-001-09-4 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.886903 | -4.111738 | -0.180041 | 0.928078 | 0.292131 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000973 |
BRD-K19687926-001-04-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.492893 | 3.939667 | 0.345966 | 1 | 2.19205 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000973 |
BRD-K19796430-001-05-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.766523 | 0.699492 | -0.180657 | 0.912516 | 0.290143 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000973 |
BRD-K22064724-001-01-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.048888 | 0.922802 | 0.713852 | 0.67991 | 0.401825 | 0.449222 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000973 |
BRD-K22822991-001-02-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.828327 | 0.357695 | 0.052268 | 0.884258 | 0.006431 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000973 |
BRD-K23228615-001-02-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.359325 | -0.017847 | -0.003499 | 1 | 0.147554 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000973 |
BRD-K23984367-001-07-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.049515 | 0.030521 | -0.001246 | 1 | 0.00001 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000973 |
BRD-K26026438-001-01-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.805098 | 1.743657 | 0.029302 | 0.88824 | 0.03829 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000973 |
BRD-K26657438-001-15-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.138997 | -0.032106 | -0.017966 | 1 | 14.373581 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000973 |
BRD-K28822270-001-03-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.021928 | -0.056508 | -0.026814 | 1 | 9.327386 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000973 |
BRD-K29905972-001-06-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.287582 | 0.72948 | 0.502517 | 0.80409 | 0.849497 | 2.74675 | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000973 |
BRD-K30577245-001-05-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.161026 | 3.502497 | 0.779407 | 0.435803 | 0.000915 | 0.001022 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000973 |
BRD-K31698212-001-02-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.447128 | -0.037113 | -0.080208 | 1 | 13,642.463668 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000973 |
BRD-K31928526-001-02-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.227809 | 0.923692 | 0.477963 | 0.749931 | 0.457652 | 0.883997 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000973 |
BRD-K33379087-001-07-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.194523 | 4.315745 | 0.750826 | 0.744259 | 0.459022 | 0.514541 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000973 |
BRD-K33610132-001-02-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.059646 | 0.125819 | -0.006919 | 1 | 0.083113 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000973 |
BRD-K33622447-066-01-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.786473 | 1.034232 | 0.168394 | 0.936248 | 0.57914 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000973 |
BRD-K35520305-001-16-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.01956 | 0.051602 | -0.000709 | 1 | 0.000046 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000973 |
BRD-K36627727-001-05-4 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.630418 | 0.453633 | 0.051555 | 0.85661 | 0.308481 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000973 |
BRD-K36788280-001-01-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.768856 | 9.507208 | 0.302192 | 0.852833 | 0.020728 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000973 |
BRD-K37379014-001-02-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.394045 | 1.766023 | 0.406297 | 0.832279 | 0.010685 | 0.025723 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000973 |
BRD-K38332599-001-01-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.23527 | -0.096506 | -0.020035 | 1 | 0.180737 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000973 |
BRD-K38852836-001-02-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.247396 | 1.730789 | 0.85355 | 0.559527 | 0.008548 | 0.012681 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000973 |
BRD-K41859756-001-06-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.269593 | 4.156063 | 0.899646 | 0.490038 | 0.00286 | 0.003446 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000973 |
BRD-K42495768-001-01-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.766514 | -2.852529 | -0.255706 | 0.924979 | 0.013789 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000973 |
BRD-K42805893-001-04-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.250413 | 1.575118 | -0.125493 | 1 | 0.033831 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000973 |
BRD-K42828737-001-03-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.420372 | 10.441065 | 0.424002 | 1 | 0.17123 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000973 |
BRD-K42898655-001-01-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.214381 | 0.353949 | 0.129236 | 1 | 0.000191 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000973 |
BRD-K43389675-001-02-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.151233 | 1.12317 | 0.699878 | 0.45471 | 0.019262 | 0.026545 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000973 |
BRD-K44408410-001-17-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.258358 | 2.789529 | 0.4246 | 0.933117 | 4.306117 | 5.588462 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000973 |
BRD-K44827188-001-06-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.231692 | -0.543978 | 0.004212 | 1 | 0.528288 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000973 |
BRD-K46386702-001-02-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.561853 | 0.203105 | 0.013575 | 0.807194 | 0.28103 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000973 |
BRD-K49328571-001-15-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 2.415035 | 0.516454 | 0.66582 | 1 | 0.395673 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000973 |
BRD-K49350383-001-14-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.179737 | 0.008863 | -0.001097 | 1 | 0.408496 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000973 |
BRD-K50010139-001-01-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.994988 | 0.210219 | 0.021095 | 1 | 3.549979 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000973 |
BRD-K50168500-001-07-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.923946 | 0.08345 | 0.00373 | 0.958641 | 0.009244 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000973 |
BRD-K51313569-001-07-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.722651 | 4.938 | 0.15278 | 0.833552 | 0.029553 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000973 |
BRD-K51791723-003-01-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | -0.052189 | 0.624714 | 0.667974 | 0.670661 | 0.606503 | 0.517378 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000973 |
BRD-K51967704-001-03-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.327549 | 1.590082 | 0.714644 | 0.661573 | 0.075657 | 0.147775 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000973 |
BRD-K52313696-001-12-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.141525 | 1.091608 | 0.138047 | 1 | 0.164654 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000973 |
BRD-K53414658-001-08-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.941089 | 0.236586 | -0.060147 | 0.976476 | 0.52683 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000973 |
BRD-K53972329-001-07-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.388499 | 0.11631 | -0.081836 | 1 | 0.159557 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000973 |
BRD-K54256913-001-08-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.420876 | 7.603112 | 0.397633 | 0.876408 | 1.260485 | 1.606376 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000973 |
BRD-K54955827-001-02-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.14768 | 0.485087 | 0.524972 | 0.678241 | 0.335488 | 0.690383 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000973 |
BRD-K54997624-001-06-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.873896 | 0.932986 | 0.514459 | 1 | 1.170224 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000973 |
BRD-K55187425-236-05-2 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.226839 | 2.166154 | 0.848006 | 0.507741 | 0.020725 | 0.027397 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000973 |
BRD-K56343971-001-14-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.619667 | 0.760306 | 0.393137 | 1 | 2.190681 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000973 |
BRD-K56981171-001-02-8 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.992091 | -0.432717 | -0.000636 | 0.995053 | 0.379628 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000973 |
BRD-K57080016-001-15-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.009209 | -0.030878 | -0.000601 | 1 | 20,573.114124 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000973 |
BRD-K57169635-001-04-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.134629 | 5.894221 | 0.362688 | 0.951676 | 5.857751 | 6.177951 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000973 |
BRD-K58435339-001-03-0 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.392916 | 9.902542 | 0.453966 | 0.687039 | 0.067185 | 0.078498 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000973 |
BRD-K58529924-001-01-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.632218 | 1.655052 | 0.391734 | 0.829776 | 0.118768 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000973 |
BRD-K58550667-001-08-7 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.143477 | 1.703983 | 0.75501 | 0.653379 | 0.012316 | 0.01502 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000973 |
BRD-K59317601-001-05-5 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.835588 | 2.739258 | 0.073221 | 0.954583 | 0.685256 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000973 |
BRD-K59369769-001-22-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.432834 | 0.948853 | 0.407097 | 0.763835 | 0.179022 | 1.485015 | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000973 |
BRD-K60866521-001-07-1 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 1.571047 | 0.208463 | 0.048223 | 1 | 1.065156 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000973 |
BRD-K60997853-001-02-3 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.716314 | 0.179432 | -0.007961 | 0.846092 | 0.02846 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000973 |
BRD-K61192372-001-08-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 2.538292 | 2.791541 | 0.521794 | 1 | 6.632993 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000973 |
BRD-K62008436-001-23-9 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.094737 | 1.573493 | 0.701825 | 0.492962 | 0.002721 | 0.00311 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000973 |
BRD-K62196610-001-01-6 | ACH-000973 | 639V_URINARY_TRACT | MTS010 | 1 | 0.718599 | 0.774982 | 0.189188 | 0.834434 | 0.031699 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000973 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.